This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gabrilove, J. L. Search for Related Content PubMed PubMed Citation Articles by Gabrilove, J. L.

Angiogenic Growth Factors: Autocrine and Paracrine Regulation of Survival in Hematologic Malignancies

Division of Medical Oncology, Department of Medicine, The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York, USA

Correspondence: Janice L. Gabrilove, M.D., Chief, Division of Medical Oncology, Department of Medicine, Deputy Director for Clinical Affairs, The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029, USA. Telephone: 212-241-9650; Fax: 212-289-0678; e-mail: janice.gabrilove{at}mssm.edu

Recent research has focused on the role of angiogenic growth factors and their ability to mediate tumor growth and metastases, both in solid tumors and in hematologic malignancies. The bone marrow microenvironment is the setting for a wealth of complex interactions that include cell-to-cell contacts as well as secretion of and response to soluble factors. Abundant evidence supports the role of basic fibroblast growth factor (bFGF) in contributing to the dysregulation of apoptosis that is the hallmark of chronic lymphocytic leukemia (CLL). In fact, CLL cells themselves express bFGF; intracellular levels of this cytokine correlate with clinical CLL stage. Other stromal factors mediate the inhibition of apoptosis in CLL as well, suggesting that strategies to block the responses of CLL cells to these factors may represent effective therapies. More broadly, the class of agents known as angiogenesis inhibitors may offer important advantages with respect to the treatment of numerous types of malignancies. Currently, a number of clinical trials are under way to evaluate the clinical potential of several different angiogenesis inhibitors in several hematologic neoplasms.

Key Words. Cancer • Leukemia • Myelodysplastic syndromes • Chemotherapy • Angiogenesis

This article has been cited by other articles:

				B. F. Taylor, S. C. McNeely, H. L. Miller, G. M. Lehmann, M. J. McCabe Jr., and J. C. States p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21CIP1/WAF1 J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 142 - 151. [Abstract] [Full Text] [PDF]

				T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]

				C. Gridelli and F. A. Shepherd Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer: A Review of the Evidence Chest, August 1, 2005; 128(2): 947 - 957. [Abstract] [Full Text] [PDF]

				L. Vincent, D. K. Jin, M. A. Karajannis, K. Shido, A. T. Hooper, W. K. Rashbaum, B. Pytowski, Y. Wu, D. J. Hicklin, Z. Zhu, et al. Fetal Stromal-Dependent Paracrine and Intracrine Vascular Endothelial Growth Factor-A/Vascular Endothelial Growth Factor Receptor-1 Signaling Promotes Proliferation and Motility of Human Primary Myeloma Cells Cancer Res., April 15, 2005; 65(8): 3185 - 3192. [Abstract] [Full Text] [PDF]

				S. D. Ramsey, N. Howlader, R. D. Etzioni, and B. Donato Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non-Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results-Medicare J. Clin. Oncol., December 15, 2004; 22(24): 4971 - 4978. [Abstract] [Full Text] [PDF]

				C. G. Azzoli, D. G. Pfister, D. H. Johnson, and M. R. Somerfield In Reply: J. Clin. Oncol., December 15, 2004; 22(24): 5020 - 5021. [Full Text] [PDF]

				P. D. Makrantonakis, E. Galani, and P. G. Harper Non-Small Cell Lung Cancer in the Elderly Oncologist, September 1, 2004; 9(5): 556 - 560. [Abstract] [Full Text] [PDF]

				S. C. R. Santos and S. Dias Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways Blood, May 15, 2004; 103(10): 3883 - 3889. [Abstract] [Full Text] [PDF]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer Oncologist, June 1, 2003; 8(3): 270 - 277. [Abstract] [Full Text] [PDF]

				G.-Q. Chen, L. Zhou, M. Styblo, F. Walton, Y. Jing, R. Weinberg, Z. Chen, and S. Waxman Methylated Metabolites of Arsenic Trioxide Are More Potent Than Arsenic Trioxide as Apoptotic but not Differentiation Inducers in Leukemia and Lymphoma Cells Cancer Res., April 15, 2003; 63(8): 1853 - 1859. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr. and R. Lilenbaum Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, March 5, 2003; 95(5): 341 - 343. [Full Text] [PDF]